Autism Care: From Access to Accountability

The landscape of autism therapy has dramatically shifted over the past two decades. Initially, access to care was a major hurdle, often requiring families to fight for services. Insurance mandates and increased awareness have since expanded access, leading to the growth of clinics and services reaching hundreds of thousands of families.

This growth has led to autism therapy becoming the fastest-growing area of Medicaid spending, which was $2.2 billion in 2023, up significantly from four years prior. This surge has attracted regulatory attention, with providers facing more audits and tighter requirements. Payers are now questioning the effectiveness of treatments, moving from a model that rewarded hours to one that seeks demonstrable outcomes.

While traditional assessment tools like VB-MAPP are valuable, they are difficult to standardize and can vary based on clinical judgment. The field is now exploring new technologies, such as digital biomarkers and eye gaze patterns, to introduce objective measurements. These new approaches aim to provide a consistent reference point for treatment efficacy, complementing existing behavioral data.

This shift towards objective measurement brings both opportunities and concerns. While it can provide clearer evidence of progress, there's a risk of misusing data or oversimplifying complex developmental gains. The industry faces a critical juncture: actively shape the future of outcome measurement, combining behavioral, functional, and objective data, or have these standards imposed externally.